These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2292201)

  • 41. Oral disposition kinetics of ofloxacin in patients with compensated liver cirrhosis.
    Orlando R; Sawadogo A; Miglioli PA; Cappellazzo MG; Palatini P
    Chemotherapy; 1992; 38(1):1-6. PubMed ID: 1617997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses.
    Odoul F; Le Guellec C; Giraut C; de Gialluly C; Marchand S; Paintaud G; Saux MC; Rolland JC; Autret-Leca E
    Therapie; 2001; 56(5):519-24. PubMed ID: 11806288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Digitoxin in patients with hepatorenal insufficiency after repeated oral administration.
    Kirch W; Ohnhaus EE; Pabst J; Storstein L
    Eur Heart J; 1989 Jan; 10(1):40-7. PubMed ID: 2702965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and residues of ciprofloxacin and its metabolites in broiler chickens.
    Anadón A; Martínez-Larrañaga MR; Iturbe J; Martínez MA; Díaz MJ; Frejo MT; Martínez M
    Res Vet Sci; 2001 Oct; 71(2):101-9. PubMed ID: 11883887
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical pharmacokinetics of enoxacin in subjects with renal or hepatic impairment.
    Novelli A; Reali EF; Amato M; Dami A; Fallani S; Periti P
    J Chemother; 1989 Jul; 1(4 Suppl):546-8. PubMed ID: 16312526
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmacokinetics of pantoprazole in man.
    Huber R; Hartmann M; Bliesath H; Lühmann R; Steinijans VW; Zech K
    Int J Clin Pharmacol Ther; 1996 May; 34(5):185-94. PubMed ID: 8738854
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of sulpiride after intravenous administration in patients with impaired renal function.
    Bressolle F; Brès J; Mourad G
    Clin Pharmacokinet; 1989 Nov; 17(5):367-73. PubMed ID: 2582694
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renal- and hepatic insufficiency.
    Krakamp B; Tanswell P; Leidig P; Vogel H; Schmitz R; Bozler G
    Eur J Clin Pharmacol; 1989; 36(1):71-3. PubMed ID: 2917592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dose ranging study and constant infusion evaluation of ciprofloxacin.
    Drusano GL; Plaisance KI; Forrest A; Standiford HC
    Antimicrob Agents Chemother; 1986 Sep; 30(3):440-3. PubMed ID: 3777907
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of high-pressure liquid chromatography and microbiological assay for determination of ciprofloxacin tablets in human plasma employed in bioequivalence and pharmacokinetics study.
    Khan MK; Khan MF; Mustafa G; Sualah M
    Pak J Pharm Sci; 2012 Jan; 25(1):81-8. PubMed ID: 22186313
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of sucralfate pretreatment on the pharmacokinetics of ciprofloxacin.
    Nix DE; Watson WA; Handy L; Frost RW; Rescott DL; Goldstein HR
    Pharmacotherapy; 1989; 9(6):377-80. PubMed ID: 2616352
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changes in metildigoxin pharmacokinetics in cirrhosis of the liver: a comparison with beta-acetyldigoxin.
    Rameis H; Woodcock B; Bonelli J; Waginger H
    Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):145-51. PubMed ID: 6715083
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and dosage regimen of ciprofloxacin following single intramuscular administration in Teddy goats.
    Iqbal Z; Javed I; Basit A; Jan I; Khan AA
    Pak J Pharm Sci; 2011 Jan; 24(1):69-74. PubMed ID: 21190922
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Femoxetine clearance in patients with liver cirrhosis.
    Hansen BA; Mengel H; Keiding S; Lund J
    Acta Pharmacol Toxicol (Copenh); 1984 Nov; 55(5):386-90. PubMed ID: 6528808
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin).
    Alestig K
    Scand J Infect Dis Suppl; 1990; 68():19-22. PubMed ID: 2218417
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
    Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs.
    Anadón A; Martínez-Larrañaga MR; Díaz MJ; Fernández-Cruz ML; Martínez MA; Frejo MT; Martínez M; Iturbe J; Tafur M
    Am J Vet Res; 1999 Nov; 60(11):1377-82. PubMed ID: 10566812
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intravenous ciprofloxacin disposition in obesity.
    Allard S; Kinzig M; Boivin G; Sörgel F; LeBel M
    Clin Pharmacol Ther; 1993 Oct; 54(4):368-73. PubMed ID: 8222478
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of cefpiramide in healthy volunteers, patients with various degrees of renal dysfunction, and patients on hemodialysis.
    Ohkawa M; Tokunaga S; Sugata T; Shimamura M; Okasho A; Hirano S; Matsui H
    Chemotherapy; 1989; 35(6):416-22. PubMed ID: 2612231
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of intravenous ciprofloxacin at three different doses.
    Ljungberg B; Nilsson-Ehle I
    J Antimicrob Chemother; 1988 Nov; 22(5):715-20. PubMed ID: 3209529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.